30798-64-2

Basic information

• Product Name: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-7-OL
• Synonyms: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-7-OL;H90101;1,2,3,4-tetrahydro-7-isoquinolinol(SALTDATA: 1.05HCl);1,2,3,4-tetrahydro-iosquinoline-7-ol;1,2,3,4-tetrahydro-7-isoquinolinol;3,4-Tetraihydro-isoquinolin-7-ol
• CAS NO: 30798-64-2
• Molecular Formula: C₉H₁₁NO
• Molecular Weight: 149.19
• EINECS: -0
• Mol File: 30798-64-2.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 313.5 °C at 760 mmHg
• Flash Point: 169.5 °C
• Appearance: /
• Density: 1.141
• Storage Temp.: 2-8°C
• PKA: 10.25±0.20(Predicted)
• CAS DataBase Reference: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-7-OL(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-7-OL(30798-64-2)
• EPA Substance Registry System: 1,2,3,4-TETRAHYDRO-ISOQUINOLIN-7-OL(30798-64-2)

Safety Data

• Hazardous Substances Data: 30798-64-2(Hazardous Substances Data)

Usage

General Description

1,2,3,4-Tetrahydro-Isoquinolin-7-ol, also known as 7-Hydroxy-1,2,3,4-tetrahydroisoquinoline, is a chemical compound with the molecular formula C9H11NO. This organic compound belongs to a group of natural products known as tetrahydroisoquinolines, which are derivatives of the isoquinoline alkaloid chemical family. An alkaloid is a chemical compound produced by a variety of organisms, and they often have pharmacological effects on humans. 1,2,3,4-Tetrahydro-Isoquinolin-7-ol's exact physical properties or specific applications are not typically discussed in the available literature, implying that it might be a subject of specialized and analytical research in the field of chemistry or biochemistry.

Upstream product

• 7651-83-4 isoquinolin-7-ol 
• 72299-68-4 1,2,3,4-Tetrahydro-isoquinolin-7-ylamine 
• 1700-37-4 3-Benzyloxybenzaldehyde 
• 51-67-2 tyrosamine 
• 109-87-5 Dimethoxymethane 

Downstream Products

• 188576-49-0 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid tert-butyl ester 
• 1552304-54-7 2-(2-chlorobenzyl)-1,2,3,4-tetrahydroisoquinolin-7-ol 
• 1315319-88-0 C₂₇H₂₃ClN₂S 

Relevant articles and documents

GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE

Described herein are compounds, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds to treat or prevent diseases or disorders associated with a defect in glyoxylate metabolism, for example a disease or disorder associated with the enzyme glycolate oxidase (GO) or alterations in oxalate metabolism. Such diseases or disorders include, for example, disorders of glyoxylate metabolism, including primary hyperoxaluria, that are associated with production of excessive amounts of oxalate.

FXR RECEPTOR MODULATOR, PREPARATION METHOD THEREFOR, AND USES THEREOF

The present disclosure disclosed a modulator of FXR receptor and preparation and use thereof, which relates to the technical filed of medicinal chemistry. The present disclosure provides a modulator of FXR receptor having a structural formula I or a pharmaceutically acceptable salt, stereoisomer, solvate or prodrug thereof, which can combine with FXR receptor (that is NR1H4) and be acted as a FXR agonist or a partial agonist for preventing and treating the disease mediated by FXR, such as chronic intrahepatic or extrahepatic cholestasis, hepatic fibrosis caused by chronic cholestasis or acute intrahepatic cholestasis, chronic hepatitis B, gallstone, hepatic carcinoma, colon cancer or intestinal inflammatory disease, etc. Specifically, for some chemical compounds, their EC50 for FXR agonist activity reach below 100nM, which show an excellent FXR agonist activity and an excellent prospect to provide a new pharmaceutical selection in clinical treatment for the disease mediated by FXR.

Identification of non-amidine inhibitors of acid-sensing ion channel-3 (ASIC3)

A series of benzothiophene methyl amines were examined in an effort to identify non-amidine chemotypes with reduced polypharmacology from existing leads with the goal of finding potent ASIC3 channel blockers to advance the therapeutic evaluation of ASIC3